Articles

Permanent URI for this collection

https://testres.nu.edu.kz/handle/123456789/4117

Browse

Browsing Articles by Subject "AKT inhibitor"

Now showing 1 - 1 of 1
  • Thumbnail Image
    ItemOpen Access
    CAPIVASERTIB RESTRICTS SARS-COV-2 CELLULAR ENTRY: A POTENTIAL CLINICAL APPLICATION FOR COVID-19
    (International Journal of Biological Sciences, 2021) Sun, Fang; Mu, Chenglin; Kwok, Hang Fai; Xu, Jiyuan; Wu, Yingliang; Liu, Wanhong; Sabatier, Jean-Marc; Annweiler, Cédric; Li, Xugang; Cao, Zhijian; Xie, Yingqiu
    Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic era